J&J's siltuximab recommended in EU for Castleman's disease
This article was originally published in Scrip
Executive Summary
The CHMP has granted a positive opinion to Janssen (Johnson & Johnson)'s high-affinity chimeric human-mouse anti-IL-6 monoclonal antibody, Sylvant (siltuximab; CNTO 328), for the treatment of multicentric Castleman's disease (MCD).